116 related articles for article (PubMed ID: 22945647)
1. C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.
Barroilhet L; Yang J; Hasselblatt K; Paranal RM; Ng SK; Rauh-Hain JA; Welch WR; Bradner JE; Berkowitz RS; Ng SW
Oncogene; 2013 Aug; 32(33):3896-903. PubMed ID: 22945647
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.
May T; Yang J; Shoni M; Liu S; He H; Gali R; Ng SK; Crum C; Berkowitz RS; Ng SW
Neoplasia; 2013 Jun; 15(6):600-8. PubMed ID: 23730208
[TBL] [Abstract][Full Text] [Related]
3. Interaction of ZEB and histone deacetylase with the PLDLS-binding cleft region of monomeric C-terminal binding protein 2.
Zhao LJ; Kuppuswamy M; Vijayalingam S; Chinnadurai G
BMC Mol Biol; 2009 Sep; 10():89. PubMed ID: 19754958
[TBL] [Abstract][Full Text] [Related]
4. Pinin interacts with C-terminal binding proteins for RNA alternative splicing and epithelial cell identity of human ovarian cancer cells.
Zhang Y; Kwok JS; Choi PW; Liu M; Yang J; Singh M; Ng SK; Welch WR; Muto MG; Tsui SK; Sugrue SP; Berkowitz RS; Ng SW
Oncotarget; 2016 Mar; 7(10):11397-411. PubMed ID: 26871283
[TBL] [Abstract][Full Text] [Related]
5. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase 4 increases progressive epithelial ovarian cancer cells via repression of p21 on fibrillar collagen matrices.
Shen YF; Wei AM; Kou Q; Zhu QY; Zhang L
Oncol Rep; 2016 Feb; 35(2):948-54. PubMed ID: 26572940
[TBL] [Abstract][Full Text] [Related]
9. Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.
Birts CN; Harding R; Soosaipillai G; Halder T; Azim-Araghi A; Darley M; Cutress RI; Bateman AC; Blaydes JP
Biol Cell; 2010 Jan; 103(1):1-19. PubMed ID: 20964627
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Lapierre M; Linares A; Dalvai M; Duraffourd C; Bonnet S; Boulahtouf A; Rodriguez C; Jalaguier S; Assou S; Orsetti B; Balaguer P; Maudelonde T; Blache P; Bystricky K; Boulle N; Cavaillès V
Oncotarget; 2016 Apr; 7(15):19693-708. PubMed ID: 26930713
[TBL] [Abstract][Full Text] [Related]
11. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
[TBL] [Abstract][Full Text] [Related]
12. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
13. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
Kwiecińska P; Wróbel A; Taubøll E; Gregoraszczuk EŁ
Toxicol Lett; 2014 Jan; 224(2):225-32. PubMed ID: 24200999
[TBL] [Abstract][Full Text] [Related]
14. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
15. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
16. Leptin Receptor Antagonists' Action on HDAC Expression Eliminating the Negative Effects of Leptin in Ovarian Cancer.
Fiedor E; Zajda K; Gregoraszczuk EL
Cancer Genomics Proteomics; 2018; 15(4):329-336. PubMed ID: 29976638
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.
Qu H; Chen Y; Cao G; Liu C; Xu J; Deng H; Zhang Z
Oncotarget; 2016 Dec; 7(50):83187-83199. PubMed ID: 27825122
[TBL] [Abstract][Full Text] [Related]
18. PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors.
Shi K; Yin X; Cai MC; Yan Y; Jia C; Ma P; Zhang S; Zhang Z; Gu Z; Zhang M; Di W; Zhuang G
Elife; 2019 May; 8():. PubMed ID: 31050342
[TBL] [Abstract][Full Text] [Related]
19. Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors.
Rodrigues Moita AJ; Bandolik JJ; Hansen FK; Kurz T; Hamacher A; Kassack MU
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167494
[TBL] [Abstract][Full Text] [Related]
20. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
Qin S; Li Y; Cao X; Du J; Huang X
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
